Preventative Medicine for Biotech Companies: Lessons from Life Sciences Securities Litigation

Please Join Us in Boston

Life sciences companies, with high-stakes clinical trials and FDA applications are increasingly targets of shareholder plaintiffs' lawyers. Unfavorable trial results and adverse FDA decisions often lead to class action securities lawsuits. This presentation provides practical tips so companies and their officers and directors can mitigate the risk of securities litigation by implementing prudent disclosure practices drawn from the rulings in recent securities class action decisions.

bio photo

Nicki Locker
Wilson Sonsini
Goodrich & Rosati

bio photo

Laurie Smilan
Of Counsel
Wilson Sonsini
Goodrich & Rosati

bio photo

Sean Coady
Senior Vice President
Woodruff Sawyer

Wednesday, September 18, 2019
8:30 a.m. Eastern – Breakfast & Registration
9:00 a.m. Eastern – Discussion

Wilson Sonsini Goodrich & Rosati
28 State Street, 37th Floor
Boston, Massachusetts
(617) 598-7800



To update your preferences for the kinds of materials you'd like to receive from us,
please click here to visit the WSGR Subscription Center.
You also can quickly unsubscribe from all WSGR mailings by clicking here.